Emmaus Sickle Cell NDA Facing FDA Concerns About Clinical Meaningfulness
Executive Summary
PGLG's application only has one Phase III trial, and Emmaus is hoping statistical re-analyses can address FDA skepticism about clinical meaningfulness of the primary endpoint data.
You may also be interested in...
Keeping Track: US FDA Approves Sickle Cell Therapy Endari; Array Submits Binimetinib Again
The latest drug development news and highlights from our FDA Performance Tracker.
Modus's Intended IPO to Spur Sickle Cell Drug R&D
The first IPO for a pharmaceutical company nurtured by Karolinska Development is expected to involve Modus Therapeutics, which has changed its name from Dilaforette and is pursuing the development of a Phase II potential sickle cell therapy.
EPIC Fail For Mast Therapeutics’ Lead Drug Sends Shares Into Freefall
Shares in Mast Therapeutics dropped by more than 80% upon news that a Phase III trial of its lead product vepoloxamer in sickle cell disease had failed.